schneider said that he is "not aware of any relevant risk of the drug" and that his team has "not observed side effects in thousands of treated animals.".
following close on aimovig's heels are three other drugs that target cgrp: fremanezumab, galcanezumab, and eptinezumab (which is given by iv)..